Co-development of novel cell produced treatments for hair follicle stimulation

共同开发新型细胞产生的毛囊刺激疗法

• 批准号: 10075601
• 金额: $ 31.22万
• 依托单位: HAIRCLONE LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10075601
• 关键词: Co; development; novel; cell; produced

HairClone in the UK and Cell Research Corporation (CRC) in Singapore will form an international collaboration to develop treatments using human cell conditioned media to transiently stimulate hair growth in patients suffering from Androgenic Alopecia. CRC are developing clinical ATMPs based on human umbilical cord lining stem cells and have also developed a conditioned media from non-human cord lining stem cells that is successfully marketed as Calecim for cosmetic skin repair. Clinicians are also beginning to use this to transiently stimulate hair growth, that is estimated to address a £100M market in the US alone. HairClone are developing a human ATMP intended to permanently rebuild miniaturising follicles (to address the £6Bn surgical hair loss market) and has developed proprietary test systems based on transcriptomic analysis of plucked hairs as well as ex-vivo hair follicle and cell culture systems.The strategy for these two grants is to firstly develop information on the transcriptomic changes in patients following Calecim. HairClone will use its grant to expand our analytical hair follicle and cell culture techniques to develop test systems to analyse both Calecim and the human cell analogue medias using both Hairclone's and CRC's GMP cell cultures. This will be combined with proteomic analysis of the medias to produce mechanism of action data that we can use to develop a regulatory route map to regulatory approval.A transiently stimulating product would provide a cost effective precursor treatment to patients ahead of receiving the much more expensive cell repair treatment from HairClone and together with the test systems that could be independently marketed.

英国的HairClone和新加坡的细胞研究公司(CRC)将结成国际合作，开发使用人类细胞条件培养液的治疗方法，以暂时刺激雄激素性脱发患者的头发生长。CRC正在开发基于人脐带衬里干细胞的临床ATMP，还开发了一种来自非人类脐带衬里干细胞的条件培养液，成功地将其命名为Calecim，用于美容皮肤修复。临床医生也开始用它来暂时刺激头发生长，据估计，仅在美国就能满足1亿GB的市场需求。HairClone正在开发一种人类ATMP，旨在永久重建微型毛囊(以满足60亿GB的手术脱发市场)，并开发了基于拔出的毛发的转录分析以及体外毛囊和细胞培养系统的专有测试系统。这两项赠款的战略是首先开发关于Calecim患者转录变化的信息。HairClone将利用其赠款扩展我们的分析毛囊和细胞培养技术，以开发测试系统，使用HairClone和CRC的GMP细胞培养来分析Calecim和人类细胞模拟介质。这将与对介质的蛋白质组分析相结合，以产生作用机制数据，我们可以使用这些数据来制定监管路线图，以获得监管部门的批准。瞬时刺激产品将在接受HairClone昂贵得多的细胞修复治疗之前为患者提供一种成本效益高的前体治疗，并与可以独立销售的测试系统一起使用。